Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Background: Several methods exist to cost hospital contacts when estimating the cost-effectiveness of a new intervention. However, the implications of choosing a particular approach remain unclear. We compare the use of the three main DRG-based national unit costs in England to determine whether choice of approach can impact on economic evaluation results. Methods: A cost-utility model was developed to compare secondary fracture prevention models of care for hip fracture patients, using data from large primary and hospital care administrative datasets in England. A healthcare and personal social services payer perspective was adopted, and utilities were informed by a meta-regression. Hospital resource use was valued using three DRG-based unit costs, and regression-based costing models were developed using data from 13,906 patients to inform the model health states. Results: Finished consultant episode (FCE)-level reference costs resulted in the highest costs on admission (£9,075) and in the year of the fracture (£14,440). Relative to FCE-level costs, spell-level tariffs led to the lowest total hospital care costs per patient within one year of fracture (-£3,691) compared to spell-level reference costs (-£2,106). At a £20,000/QALY threshold, using spell-level reference costs or spell-level tariffs, the introduction of a nurse-led FLS model of care was the cost-effective alternative. However, using FCE-level reference costs, usual care was the cost-effective option. Conclusions: Our results show that conditional on the set of national unit costs adopted, the costs of hip fracture may vary considerably and different decisions may be reached regarding the introduction of new healthcare interventions.

Original publication

DOI

10.1007/s40273-018-0673-y

Type

Journal

PharmacoEconomics

Publication Date

22/05/2018